Cargando…
Elevating acetyl-CoA levels reduces aspects of brain aging
Because old age is the greatest risk factor for dementia, a successful therapy will require an understanding of the physiological changes that occur in the brain with aging. Here, two structurally distinct Alzheimer's disease (AD) drug candidates, CMS121 and J147, were used to identify a unique...
Autores principales: | Currais, Antonio, Huang, Ling, Goldberg, Joshua, Petrascheck, Michael, Ates, Gamze, Pinto-Duarte, António, Shokhirev, Maxim N, Schubert, David, Maher, Pamela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882557/ https://www.ncbi.nlm.nih.gov/pubmed/31742554 http://dx.doi.org/10.7554/eLife.47866 |
Ejemplares similares
-
Targeting of intracellular Ca(2+) stores as a therapeutic strategy against age-related neurotoxicities
por: Goldberg, Joshua, et al.
Publicado: (2020) -
CMS121, a fatty acid synthase inhibitor, protects against excess lipid peroxidation and inflammation and alleviates cognitive loss in a transgenic mouse model of Alzheimer's disease
por: Ates, Gamze, et al.
Publicado: (2020) -
SUMMER, a shiny utility for metabolomics and multiomics exploratory research
por: Huang, Ling, et al.
Publicado: (2020) -
Intracellular amyloid toxicity induces oxytosis/ferroptosis regulated cell death
por: Huang, Ling, et al.
Publicado: (2020) -
The mitochondrial ATP synthase is a shared drug target for aging and dementia
por: Goldberg, Joshua, et al.
Publicado: (2018)